Is Alembic Pharmaceuticals the Best Stock in Its Sector? A Look at the Numbers

Alembic Pharmaceuticals CMP Rs 823 (15 Sep 2026). Market cap Rs 15,964 Cr. ROE 11.89%. P/E 23.15x versus Industry P/E 37.96x.

Updated: 15 Sept 2026 • 10:39 am

Posted by:

Is Alembic Pharmaceuticals the Best Stock in Its Sector? A Look at the Numbers

Quick Answer

Alembic Pharmaceuticals is one of the names investors compare when screening the Healthcare sector, built on a 11.89% return on equity and a P/E of 23.15x against an Industry P/E of 37.96x. Alembic Pharmaceuticals Ltd manufactures generic formulations and active pharmaceutical ingredients for domestic and export markets, including the regulated US market, alongside a growing specialty and oncology portfolio. Whether Alembic Pharmaceuticals is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.

Is Alembic Pharmaceuticals the best stock in its sector? The stock trades on the NSE at Rs 823 as of 15 September 2026, within its 52-week range of Rs 635.80 to Rs 998.00. Alembic Pharmaceuticals Ltd manufactures generic formulations and active pharmaceutical ingredients for domestic and export markets, including the regulated US market, alongside a growing specialty and oncology portfolio.

Alembic Pharmaceuticals sits in the Healthcare sector, and its 11.89% ROE and 23.15x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.

Click Here – Get Free Investment Predictions

Table of Contents

About Alembic Pharmaceuticals

Alembic Pharmaceuticals Ltd manufactures generic formulations and active pharmaceutical ingredients for domestic and export markets, including the regulated US market, alongside a growing specialty and oncology portfolio. At a market capitalisation of Rs 15,964 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Alembic Pharmaceuticals the Best Stock in Its Sector?

Alembic Pharmaceuticals makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 11.89% ROE with a 23.15x P/E against the sector’s 37.96x Industry P/E. Alembic Pharmaceuticals’ 23.15x P/E is a clear discount to the 37.96x Industry P/E, though its 11.89% ROE trails larger MNC pharma peers, so the discount partly reflects lower current returns on capital.

Metric	Alembic Pharmaceuticals
CMP (NSE)	Rs 822.80
52-Week High / Low	Rs 998.00 / Rs 635.80
Market Cap	Rs 15,964 Cr
P/E (TTM) vs Industry P/E	23.15x vs 37.96x
P/B	2.81
ROE	11.89%
EPS (TTM)	Rs 35.08
Dividend Yield	1.48%
Debt to Equity	0.25

Compare Alembic Pharmaceuticals Against Other Healthcare Sector Stocks

How Alembic Pharmaceuticals Compares Against Its Healthcare Sector Peers

The table below sets Alembic Pharmaceuticals against 3 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 3 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Alembic Pharmaceuticals	15,964	23.15	11.89%	0.25
Pfizer	18,583	25.28	17.19%	0.02
Sanofi India	7,093	21.91	39.20%	0.02
GlaxoSmithKline Pharmaceuticals	48,064	45.00	45.69%	0.01
Peer average (3 companies)	–	30.73	34.03%	0.02

Against this peer set, Alembic Pharmaceuticals’s 11.89% ROE is below the 34.03% peer average, and its P/E of 23.15x runs below the peer average of 30.73x. Alembic Pharmaceuticals’ 23.15x P/E is a clear discount to the 37.96x Industry P/E, though its 11.89% ROE trails larger MNC pharma peers, so the discount partly reflects lower current returns on capital.

What Makes Alembic Pharmaceuticals Worth Watching in Healthcare

Well below Industry P/E: A 23.15x P/E against a 37.96x Industry P/E makes Alembic one of the more reasonably priced names in the Healthcare sector on this metric.
Low leverage: A debt to equity ratio of 0.25 leaves room for continued capacity expansion and R&D spending without straining the balance sheet.
Export and API diversification: Exposure to both export formulations and API manufacturing spreads Alembic’s revenue across multiple pharma sub-segments.

Alembic Pharmaceuticals Valuation: Is It Justified?

Alembic Pharmaceuticals’ 23.15x P/E is a clear discount to the 37.96x Industry P/E, though its 11.89% ROE trails larger MNC pharma peers, so the discount partly reflects lower current returns on capital. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Download the Univest iOS App or Univest Android App to track Alembic Pharmaceuticals and other Healthcare sector stocks.

How to Track Alembic Pharmaceuticals Before You Invest

Before deciding whether Alembic Pharmaceuticals deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

Open the Univest Screener and search for Alembic Pharmaceuticals to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Alembic Pharmaceuticals earns a place in the best stock in its sector conversation on the strength of a 11.89% ROE and a P/E of 23.15x against a 37.96x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Is Alembic Pharmaceuticals the best stock in its sector?

Ans. Alembic Pharmaceuticals has a 11.89% ROE and trades at 23.15x P/E against a 37.96x Industry P/E, and compares below the peer average ROE of 34.03% in this article’s named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Alembic Pharmaceuticals?

Ans. Alembic Pharmaceuticals was trading at Rs 822.80 on the NSE as of 15 September 2026, within its 52-week range of Rs 635.80 to Rs 998.00.

What sector does Alembic Pharmaceuticals belong to?

Ans. Alembic Pharmaceuticals is classified under the Healthcare sector on Univest.

How does Alembic Pharmaceuticals compare to its sector peers on P/E?

Ans. Alembic Pharmaceuticals’s P/E of 23.15x is below the 30.73x average of the 3 named peers compared in this article.

What is Alembic Pharmaceuticals’s return on equity?

Ans. Alembic Pharmaceuticals reported a return on equity of 11.89%, which is below the 34.03% average of its named peers in this comparison.

Should I invest in Alembic Pharmaceuticals based on its sector position?

Ans. Alembic Pharmaceuticals’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.